ATHEROGENICS
AtheroGenics is a pharmaceutical company developing Antioxidants.
ATHEROGENICS
Industry:
Biotechnology Health Care Medical
Founded:
1994-01-01
Address:
Alpharetta, Georgia, United States
Country:
United States
Website Url:
http://www.atherogenics.com
Status:
Active
Technology used in webpage:
U.S. Server Location
Similar Organizations
Afmedica
Afmedica is a private company developing products to prevent the excess scarring.
ASTA Medica
ASTA Medica is a pharmaceutical company that develops drugs for the treatment of cancer.
Pharmathen
Pharmathen is a private pharmaceutical company developing generic drugs.
XBiotech
XBiotech is a biopharmaceutical company developing antibody therapies.
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.atherogenics.com
- Host name: 152.160.216.153
- IP address: 152.160.216.153
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AtheroGenics"
AtheroGenics - Crunchbase Company Profile & Funding
AtheroGenics is a pharmaceutical company developing Antioxidants. View contacts for AtheroGenics to access new leads and connect with decision-makers.See details»
Atherogenics Company Profile 2024: Valuation, Funding
Atherogenics General Information Description. Developer of treatments and drugs for inflammatory disease intended to better treat diseases. The company leverages technology to …See details»
AtheroGenics Company Profile | Management and Employees List
AtheroGenics is studying AGI-1067 in a Phase III clinical trial called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) to assess the ability of AGI-1067 to control blood sugar …See details»
AtheroGenics - Overview, News & Similar companies - ZoomInfo
Who is AtheroGenics. AtheroGenics is a publicly traded, emerging pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceutical …See details»
AtheroGenics, Inc. - SEC.gov
AtheroGenics, Inc. (Exact name of Registrant as specified in its charter) Georgia : 58-2108232 (State or other jurisdiction of (I.R.S. Employer Identification Number) incorporation or …See details»
AtheroGenics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore AtheroGenics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 2 news, and 48 literature, Drug:Elsibucol, AGI-1000 ...See details»
Atherogenics Inc - Company Profile and News - Bloomberg Markets
Company profile page for Atherogenics Inc including stock price, company news, executives, board members, and contact informationSee details»
AtheroGenics - Contacts, Employees, Board Members, Advisors
AtheroGenics is a pharmaceutical company developing Antioxidants. Start Free Trial . Chrome ExtensionSee details»
Atherogenics - Company Profile - Tracxn
Oct 22, 2024 Atherogenics - Novel treatment for inflammation of arteries in Diabetes and Cardiovascular diseases. Public Company. Raised a total funding of $20.6M over 2 rounds …See details»
Atherogenics - Products, Competitors, Financials, Employees ...
Atherogenics was founded in 1993. Where is Atherogenics's headquarters? Atherogenics's headquarters is located at 8995 Westside Parkway, Alpharetta. What is Atherogenics's latest …See details»
AtheroGenics Inc. Information - CareersInPharmaceutical.com
AtheroGenics has a dynamic employee base of approximately 100, nearly two-thirds of whom hold advanced degrees, including M.D.'s, Ph.D.'s and Masters' degrees. Our experienced …See details»
AtheroGenics - Tech Stack, Apps, Patents & Trademarks
AtheroGenics is a pharmaceutical company developing Antioxidants. Start Free Trial . Chrome ExtensionSee details»
AtheroGenics, Inc. | Insights
May 19, 2014 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
AtheroGenics goes bankrupt - Fierce Biotech
Oct 7, 2008 AtheroGenics plans to sell the company and/or its key assets as part of the bankruptcy proceedings. AtheroGenics has been developing AGI-1067, a promising diabetes …See details»
AtheroGenics enriches drug discovery pipeline with acquisition of …
Jul 12, 2001 AtheroGenics, Inc., an emerging pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it has entered into an …See details»
Are small biotechs still underselling themselves? - Nature
As AtheroGenics prepares to wrap up phase 3 trial sites for its lead atherosclerosis compound, small molecule AGI-1067, the future could suddenly become very bright for this tiny research …See details»
AtheroGenics Files for Chapter 11 Bankruptcy | Fierce Biotech
Oct 7, 2008 AtheroGenics Files for Chapter 11 Bankruptcy ATLANTA, GA -- (MARKET WIRE) -- 10/07/2008 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on …See details»
Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics …
Feb 1, 2006 AstraZeneca agreed in late December to pay AtheroGenics a $50 million upfront fee and another $950 million in regulatory and commercial milestones for the biotech's VCAM-I …See details»
Alpharetta's AtheroGenics consents to bankruptcy
Oct 7, 2008 AtheroGenics consented to the involuntary Chapter 7 bankruptcy petition filed Sept. 15 in the U.S. Bankruptcy Court for the Northern District of Georgia. It has sought to convert …See details»
AtheroGenics drug cuts death, diabetes risk-study - NBC News
Mar 27, 2007 AtheroGenics Inc.'s experimental heart drug missed the primary goal of a pivotal late-stage trial but cut death, heart attack and stroke and dramatically reduced the risk patients …See details»